Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday ↗

December 07, 2022

U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Shares of Mirati Therapeutics Fell Tuesday ↗

December 06, 2022

Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 06, 2022

Via Benzinga

Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday ↗

December 06, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

4 Analysts Have This to Say About Mirati Therapeutics ↗

November 09, 2022

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About Mirati Therapeutics ↗

September 26, 2022

Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Mirati's Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer ↗

September 08, 2022

Via Benzinga

Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗

December 06, 2022

Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...

Via Benzinga

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up ↗

December 06, 2022

The combination with Keytruda appears safe, but effectiveness questions persist.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 06, 2022

Via Benzinga

Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket ↗

December 06, 2022

Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 06, 2022

Good morning, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Via InvestorPlace

Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy ↗

December 06, 2022

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle ↗

November 23, 2022

There are reportedly numerous companies in the mix and they're all awaiting data next month.

Via Investor's Business Daily

MRTX Stock Alert: What to Know as Mirati Therapeutics Considers Potential Takeover ↗

November 23, 2022

Mirati Therapeutics (MRTX) stock is a hot topic on Wednesday as the cancer drugmaker considers strategic alternatives, such as a takeover.

Via InvestorPlace

Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month ↗

November 23, 2022

Mirati Therapeutics Inc (NASDAQ: MRTX) is reportedly amid fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline. For some time, the cancer-focused company...

Via Benzinga

Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

November 15, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...

Via FinancialNewsMedia

Topics Death

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday ↗

November 23, 2022

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...

Via Benzinga

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗

November 09, 2022

Biotech stocks were hammered Wednesday, including several that had good news.

Via Investor's Business Daily

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

November 07, 2022

From Incyte and Mirati

Via Business Wire

What 4 Analyst Ratings Have To Say About Mirati Therapeutics ↗

October 28, 2022

Over the past 3 months, 4 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022 ↗

October 28, 2022

Upgrades

Via Benzinga

4 Biotech Stocks With Huge Incoming Catalysts ↗

October 12, 2022

All four of these drugmakers are expecting important FDA approval decisions over the next few months.

Via The Motley Fool

What 4 Analyst Ratings Have To Say About Mirati Therapeutics ↗

September 26, 2022

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022 ↗

September 15, 2022

Upgrades

Via Benzinga

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost ↗

August 31, 2022

Amgen says Lumakras beat out chemo in patients with non small-cell lung cancer.

Via Investor's Business Daily

Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday ↗

August 31, 2022

Barnes & Noble Education, Inc. (NYSE: BNED) gained 16.8% to $2.64 after reporting upbeat quarterly sales. Bausch Health Companies Inc. (NYSE: BHC) gained 15.5% to $5.91.

Via Benzinga

Whither Small Caps After Fed’s Tough Talk? ↗

August 29, 2022

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.